Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Fig. 1

A 74-year-old patient with hormone- and chemo-refractory prostate cancer underwent PSMA PET/CT (a), which showed diffuse abdominal and iliacal lymph node metastases. The patient underwent RLT with 5.7 GBq Lu-PSMA. The PSA level was at the time of the therapy 790 ng/ml. b A partial response 7 weeks after RLT with 63 % PSA decline; at this time, the PSA level was 293 ng/ml

Back to article page